Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- HFpEF: Prevalence, research on effective treatment options continue to grow
-
- Timothy Henry, MD, discusses the transformation of STEMI systems of care
- Smartphone app offers online access to QT-prolonging drugs database Raymond L. Woosley, MD, PhD
- FDA panel: More data needed for embolic protection device for TAVR procedures
- First dedicated coronary bifurcation stent receives FDA approval
- Nanocoated coronary stent system receives FDA approval
- Sensor-enabled cardiac ablation catheter approved by FDA
- 2 decades of AF
- Cardiology Today names leading early career innovators
-
- Adherence to dietary recommendations linked to small improvement in weight, CHD risk factors
- Anti-Müllerian hormone trajectories associated with CVD
- Dietary factors linked to high proportion of deaths from stroke, heart disease, type 2 diabetes
- ICD shocks increase health care costs
- Increase in noncalcified plaque associated with testosterone treatment in older men
- MagnaSafe published: MRI safe for patients with pacemakers, ICDs, regardless of labeling
- Most women fail to complete cardiac rehab after acute MI
- Parents of children with severe heart defects at risk for anxiety, depression, PTSD, stress
-
- Pokémon Go confers greater likelihood of reaching 10,000 daily steps
- Statin use up, but disparities remain
- Stroke risk may be linked to menstruation onset
- Tablet application improves medication adherence in patients with DES
- Women with nonobstructive CAD exhibit reduced health status, more psychosocial distress vs. men
- CMS: Evidence sufficient to cover supervised exercise therapy for intermittent claudication
- ASSORT: Timing of statin therapy does not affect physical disability in patients with acute ischemic stroke
- ASTER: Contact aspiration comparable to stent retrievers for thrombectomy in ischemic stroke
-
- Bococizumab yields varying effects on CV events, LDL in SPIRE trials
- Direct transfer to ‘angio-suite’ decreased stroke treatment time
- EINSTEIN-CHOICE: Recurrent VTE lower with rivaroxaban vs. aspirin, without rise in bleeding
- FOURIER: Reducing LDL to very low levels with evolocumab confers reduced risk for CV events
- Increased intake of fruits, vegetables could save lives globally
- PICASSO: Cilostazol similar to aspirin for reduction of CV events in patients with ischemic stroke, TIA
- RE-CIRCUIT: Uninterrupted dabiagtran confers less bleeding risk vs. warfarin during AF catheter ablation
- SURTAVI: TAVR noninferior to surgery in intermediate-risk patients
-
- TARDIS: Intensive antiplatelet regimen not superior to guideline therapy for prevention of recurrent stroke, TIA
- Trial Scorecard: ASSORT
- Trial Scorecard: ASTER
- Trial Scorecard: EQUATOR
- Trial Scorecard: IU-FIRM
- Trial Scorecard: OSLER-1
- Trial Scorecard: REMEDEE-OCT
- Trial Scorecard: STOP-CHAGAS
-
- Trial Scorecard: TARDIS